Sign In
20 Sep 2022 07:00
20 September 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")
New Corporate Presentation
Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development and commercial production of polymer modification, biological supplements, and nano-drug delivery systems, is pleased to announce that an updated corporate presentation is now available on its website: https://graftpolymer.com/.
**ENDS**
For more information, please visit https://www.graftpolymer.com or contact:
Graft Polymer (UK) Plc | via St Brides Partners |
Roby Zomer, Chairman | |
Yifat Steuer, CFO | |
Turner Pope Investments (Broker) | +44 20 3657 0050 |
James Pope | |
Andy Thacker | |
St Brides Partners (Public Relations) | |
Catherine Leftley | graftpolymer@stbridespartners.co.uk |
Ana Ribeiro Max Bennett |
About Graft Polymer
Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, cash-flow positive, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.
Graft Polymer has three divisions: the first division focusses on polymer modification; the second is GraftBio which develops IP for Bio/Pharma applications (including a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic); and the third is the Group's food supplement division. A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate. The HACCP Certificate allows it to enter the lucrative Business-to-Consumer market and commercialise its IP for bio/pharma applications, developing active pharmaceutical ingredients and drug delivery platforms for use in the food supplement market, thereby introducing a further revenue stream to its business.
Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.
Graft Polymer is well funded and debt free.
Follow the stocks
